Should I buy or sell AlloVir stock right now?

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for AlloVir in the last year. There are currently 2 sell ratings, 3 hold ratings and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "reduce" ALVR shares. View ALVR analyst ratings or view top-rated stocks .

What is AlloVir's stock price target for 2024?

6 equities research analysts have issued twelve-month price objectives for AlloVir's shares. Their ALVR share price targets range from $17.00 to $20.00. On average, they anticipate the company's stock price to reach $18.67 in the next twelve months. This suggests a possible upside of 2,366.2% from the stock's current price. View analysts price targets for ALVR or view top-rated stocks among Wall Street analysts .

How have ALVR shares performed in 2024?

AlloVir's stock was trading at $0.6798 at the beginning of the year. Since then, ALVR stock has increased by 11.3% and is now trading at $0.7569. View the best growth stocks for 2024 here .

When is AlloVir's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024. View our ALVR earnings forecast .

How were AlloVir's earnings last quarter?

AlloVir, Inc. (NASDAQ:ALVR) issued its quarterly earnings data on Friday, March, 15th. The company reported ($0.53) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.43) by $0.10.

What other stocks do shareholders of AlloVir own?

Based on aggregate information from My MarketBeat watchlists, some companies that other AlloVir investors own include Advanced Micro Devices (AMD) , Cloudera (CLDR) , Infinera (INFN) , Sonos (SONO) , Trevena (TRVN) , Abbott Laboratories (ABT) , Boeing (BA) , Delta Air Lines (DAL) , Datadog (DDOG) and FuelCell Energy (FCEL) .

When did AlloVir IPO?

AlloVir (ALVR) raised $252 million in an initial public offering on Thursday, July 30th 2020. The company issued 14,800,000 shares at $16.00-$18.00 per share. Morgan Stanley, J.P. Morgan, SVB Leerink and Piper Sandler acted as the underwriters for the IPO.

How do I buy shares of AlloVir?

Shares of ALVR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:ALVR

AlloVir (ALVR) Stock Price, News & Analysis

→ The “Perfect Storm” for Gold (From Gold Safe Exchange) (Ad)

Free ALVR Stock Alerts

$0.76

+0.02 (+2.71%)

(As of 04/17/2024 ET)

Compare

Today's Range: $0.72
▼
$0.77
50-Day Range: $0.67
▼
$0.80
52-Week Range: $0.62
▼
$6.12

Volume: 572,247 shs
Average Volume: 1.23 million shs
Market Capitalization: $86.96 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $18.67

Get AlloVir alerts:

AlloVir MarketRank™ Stock Analysis

Analyst Rating: Reduce
1.83 Rating Score
Upside/Downside: 2,366.2% Upside
$18.67 Price Target
Short Interest: Bearish
5.48% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: Selling Shares
$69,677 Sold Last Quarter
Proj. Earnings Growth: Growing
From ($0.47) to ($0.35) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.59 out of 5 stars

Medical Sector

659th out of 913 stocks

Biological Products, Except Diagnostic Industry

112th out of 152 stocks

2.9

Analyst's Opinion

Consensus Rating
AlloVir has received a consensus rating of Reduce. The company's average rating score is 1.83, and is based on 1 buy rating, 3 hold ratings, and 2 sell ratings.
Amount of Analyst Coverage
AlloVir has received no research coverage in the past 90 days.

1.0

Short Interest

Percentage of Shares Shorted
5.48% of the outstanding shares of AlloVir have been sold short.
Short Interest Ratio / Days to Cover
AlloVir has a short interest ratio ("days to cover") of 5.2.
Change versus previous month
Short interest in AlloVir has recently increased by 0.48%, indicating that investor sentiment is decreasing.

0.0

Dividend Strength

Dividend Yield
AlloVir does not currently pay a dividend.
Dividend Growth
AlloVir does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for ALVR.

0.6

News and Social Media Coverage

Search Interest
3 people have searched for ALVR on MarketBeat in the last 30 days. This is an increase of 50% compared to the previous 30 days.
MarketBeat Follows
Only 1 people have added AlloVir to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

4.2

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, AlloVir insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $69,677.00 in company stock.
Percentage Held by Insiders
39.97% of the stock of AlloVir is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
66.05% of the stock of AlloVir is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

1.3

Earnings and Valuation

Earnings Growth
Earnings for AlloVir are expected to grow in the coming year, from ($0.47) to ($0.35) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of AlloVir is -0.41, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of AlloVir is -0.41, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
AlloVir has a P/B Ratio of 0.59. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Gold Safe Exchange

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

Click here now to download the free Precious Metals Buying Guide!

About AlloVir Stock (NASDAQ:ALVR)

Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. Its preclinical and clinical development product candidates include ALVR106 for the respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109 to treat SARS-CoV-2 and COVID-19; ALVR107 for treating hepatitis B; and ALVR108. The company was formerly known as ViraCyte, Inc. and changed its name to Allovir, Inc. in May 2019. The company was incorporated in 2013 and is based in Waltham, Massachusetts.

ALVR Stock Price History

30 days | 90 days | 365 days | Advanced Chart

ALVR Stock News Headlines

March 21, 2024 | stockhouse.com

DEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of AlloVir

March 19, 2024 | prnewswire.com

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in AlloVir, Inc. of Class Action Lawsuit and Upcoming Deadlines - ALVR

April 18, 2024 | Gold Safe Exchange (Ad)

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

March 19, 2024 | stockhouse.com

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of AlloVir

March 18, 2024 | investorplace.com

ALVR Stock Earnings: AlloVir Misses EPS for Q4 2023

March 17, 2024 | businesswire.com

ALVR DEADLINE TUESDAY: ROSEN, A LEADING LAW FIRM, Encourages AlloVir, Inc. Investors With Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities ...

March 17, 2024 | businesswire.com

ALVR DEADLINE TUESDAY: ROSEN, A LEADING LAW FIRM, Encourages AlloVir, Inc. Investors With Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action – ALVR

March 15, 2024 | stockhouse.com

4-DAY DEADLINE ALERT: The Schall Law Firm Encourages Investors in AlloVir, Inc. with Losses of $100,000 to Contact the Firm

April 18, 2024 | Gold Safe Exchange (Ad)

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

March 15, 2024 | prnewswire.com

ALVR LAWSUIT ALERT: Levi & Korsinsky Notifies AlloVir, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline

March 14, 2024 | prnewswire.com

Class Action Filed Against AlloVir, Inc. (ALVR) Seeking Recovery for Investors - Contact The Gross Law Firm

March 14, 2024 | stockhouse.com

5-DAY DEADLINE ALERT: The Schall Law Firm Encourages Investors in AlloVir, Inc. with Losses of $100,000 to Contact the Firm

March 12, 2024 | prnewswire.com

ALVR IMPORTANT DEADLINE: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages AlloVir, Inc. Investors to Secure Counsel Before Important March 19 Deadline in Securities Class Action - ALVR

March 12, 2024 | prnewswire.com

AlloVir, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before March 19, 2024 to Discuss Your Rights - ALVR

March 11, 2024 | markets.businessinsider.com

DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of AlloVir

March 9, 2024 | markets.businessinsider.com

SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of AlloVir

March 8, 2024 | markets.businessinsider.com

ALLOVIR INVESTOR ALERT: Kirby McInerney LLP Alerts AlloVir, Inc. (ALVR) Investors of Upcoming Lead Plaintiff Deadline in Class Action Lawsuit

March 7, 2024 | prnewswire.com

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of March 19, 2024 in AlloVir, Inc. Lawsuit - ALVR

March 6, 2024 | prnewswire.com

Lost Money on AlloVir, Inc.(ALVR)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky

March 5, 2024 | prnewswire.com

ROSEN, A LEADING LAW FIRM, Encourages AlloVir, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ALVR

March 3, 2024 | prnewswire.com

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in AlloVir, Inc. of Class Action Lawsuit and Upcoming Deadlines - ALVR

February 29, 2024 | msn.com

SHAREHOLDER ALERT: Potential Recovery for AlloVir, Inc. (ALVR) Investors

February 27, 2024 | stockhouse.com

SHAREHOLDER ACTION NOTICE: The Schall Law Firm Encourages Investors in AlloVir, Inc. with Losses of $100,000 to Contact the Firm

February 27, 2024 | prnewswire.com

Shareholders that lost money on AlloVir, Inc.(ALVR) should contact Levi & Korsinsky about pending Class Action - ALVR

February 25, 2024 | prnewswire.com

ROSEN, NATIONAL TRIAL LAWYERS, Encourages AlloVir, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - ALVR

February 23, 2024 | prnewswire.com

Levi & Korsinsky Notifies Shareholders of AlloVir, Inc.(ALVR) of a Class Action Lawsuit and an Upcoming Deadline

February 22, 2024 | markets.businessinsider.com

AlloVir Investor Deadline Approaching

See More Headlines

Receive ALVR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for AlloVir and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/15/2024
Today: 4/18/2024
Next Earnings (Estimated): 5/02/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Current Symbol: NASDAQ:ALVR
CUSIP: N/A
CIK: 1754068
Web: www.allovir.com
Phone: 617-433-2605
Fax: N/A
Employees: 112
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $18.67
High Stock Price Target: $20.00
Low Stock Price Target: $17.00
Potential Upside/Downside: +2,366.2%
Consensus Rating: Reduce
Rating Score (0-4): 1.83
Research Coverage: 6 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.84)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-190,420,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -99.73%
Return on Assets: -78.86%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 6.61
Quick Ratio: 6.61

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $1.28 per share
Price / Book: 0.59

Miscellaneous

Outstanding Shares: 114,885,000
Free Float: 68,965,000
Market Cap: $86.96 million
Optionable: Optionable
Beta: 0.86

The Best High-Yield Dividend Stocks for 2024

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

Key Executives

Mr. David L. Hallal (Age 58)
Executive Chairman of the Board
Comp: $254.38k
Dr. Diana M. Brainard M.D. (Age 52)
CEO & Director
Comp: $978.99k
Mr. Vikas Sinha C.A. (Age 61)
CPA, M.B.A., President, CFO & Director
Comp: $536.21k
Mr. Edward Miller J.D. (Age 59)
General Counsel & Secretary
Comp: $618.39k
Mr. Brett R. Hagen (Age 51)
Chief Accounting Officer
Mr. Dana M. Alexander (Age 48)
Senior Vice President of Technical Operations
Dr. Ann M. Leen Ph.D. (Age 46)
Chief Scientific Officer
Mr. Ugo Capolino Perlingieri
Head & GM of Europe and Middle East Operations
Ms. Cintia Piccina Pharm.D. (Age 50)
Chief Commercial Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

ALVR Stock Analysis - Frequently Asked Questions

Should I buy or sell AlloVir stock right now?: 6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for AlloVir in the last year. There are currently 2 sell ratings, 3 hold ratings and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "reduce" ALVR shares.
View ALVR analyst ratings or view top-rated stocks.
What is AlloVir's stock price target for 2024?: 6 equities research analysts have issued twelve-month price objectives for AlloVir's shares. Their ALVR share price targets range from $17.00 to $20.00. On average, they anticipate the company's stock price to reach $18.67 in the next twelve months. This suggests a possible upside of 2,366.2% from the stock's current price.
View analysts price targets for ALVR or view top-rated stocks among Wall Street analysts.
How have ALVR shares performed in 2024?: AlloVir's stock was trading at $0.6798 at the beginning of the year. Since then, ALVR stock has increased by 11.3% and is now trading at $0.7569.
View the best growth stocks for 2024 here.
When is AlloVir's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024.
View our ALVR earnings forecast.

How were AlloVir's earnings last quarter?: AlloVir, Inc. (NASDAQ:ALVR) issued its quarterly earnings data on Friday, March, 15th. The company reported ($0.53) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.43) by $0.10.
What other stocks do shareholders of AlloVir own?: Based on aggregate information from My MarketBeat watchlists, some companies that other AlloVir investors own include Advanced Micro Devices (AMD), Cloudera (CLDR), Infinera (INFN), Sonos (SONO), Trevena (TRVN), Abbott Laboratories (ABT), Boeing (BA), Delta Air Lines (DAL), Datadog (DDOG) and FuelCell Energy (FCEL).
When did AlloVir IPO?: AlloVir (ALVR) raised $252 million in an initial public offering on Thursday, July 30th 2020. The company issued 14,800,000 shares at $16.00-$18.00 per share. Morgan Stanley, J.P. Morgan, SVB Leerink and Piper Sandler acted as the underwriters for the IPO.
How do I buy shares of AlloVir?: Shares of ALVR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ALVR) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

AlloVir (ALVR) Stock Price, News & Analysis

AlloVir MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About AlloVir Stock (NASDAQ:ALVR)

ALVR Stock Price History

ALVR Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

ALVR Stock Analysis - Frequently Asked Questions

Overall MarketRank^™